Premium
Risk of Torsades de Pointes From Oral Erythromycin with Concomitant Carbimazole (Methimazole) Administration
Author(s) -
KOH TAT W.
Publication year - 2001
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1046/j.1460-9592.2001.01575.x
Subject(s) - carbimazole , medicine , torsades de pointes , erythromycin , concomitant , pharmacology , oral administration , qt interval , pharmacodynamics , pharmacokinetics , anesthesia , antibiotics , graves' disease , disease , microbiology and biotechnology , biology
KOH, T.W.: Risk of Torsades de Pointes From Oral Erythromycin with Concomitant Carbimazole (Methimazole) Administration. There are many reports of intravenous erythromycin causing QT prolongation and torsades de pointes, but this complication is seldom ascribed to orally administered erythromycin, which is by far the most commonly prescribed route. This report describes a case of torsades de pointes associated with oral erythromycin as a result of a previously undescribed interaction with carbimazole, an antithyroid drug that is metabolized to the active drug methimazole, and the potential pharmacokinetic and pharmacodynamic mechanisms are highlighted.